Related Experiment Videos
[The effect of cerebrocrast on erythrocyte function]
Eksperimental'Naia I Klinicheskaia Farmakologiia
|May 1, 1993
Summary
The new drug cerebrocrast prevents red blood cell (RBC) deformability issues during and after cerebral ischemia in rats. It also reduces RBC aggregation and oxygen binding, potentially by increasing 2,3-DPG levels.
Area of Science:
- Neuroscience
- Hematology
- Pharmacology
Background:
- Cerebral ischemia can lead to erythrocyte (red blood cell) deformability disturbances.
- These disturbances can worsen blood flow and neurological damage.
- Cerebrocrast is a novel calcium antagonist investigated for neuroprotective effects.
Purpose of the Study:
- To evaluate the effect of cerebrocrast on erythrocyte deformability during and after cerebral ischemia.
- To assess cerebrocrast's impact on erythrocyte aggregation and hemoglobin-oxygen affinity.
Main Methods:
- Cerebral ischemia was induced in rats via carotid artery occlusion for 30 minutes.
- Cerebrocrast was administered intravenously at a dose of 0.4 µg/kg/min for 15 minutes.
- Erythrocyte deformability, aggregation, and hemoglobin-oxygen affinity were measured.
Main Results:
- Cerebrocrast prevented erythrocyte deformability disturbances at the end of ischemia and 1 hour post-reperfusion.
- The drug reduced spontaneous erythrocyte aggregation and the strength of aggregates.
- Cerebrocrast decreased hemoglobin affinity for oxygen, linked to increased erythrocytic 2,3-diphosphoglycerate.
Conclusions:
- Cerebrocrast demonstrates protective effects on erythrocyte function during cerebral ischemia.
- The drug may mitigate ischemia-induced microcirculatory dysfunction.
- Cerebrocrast's mechanism involves modulation of erythrocyte aggregation and oxygen release.